The recent approval of PARP inhibitors for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA mutations firstly introduced the possibility of proposing a targeted treatment in this disease.
However, the availability of this therapeutic option raises a number of questions concerning the management of prostate cancer in everyday clinical practice: the timing and method of detecting BRCA mutations, the therapeutic implications of the detection, and the screening of the members of the family of a prostate cancer patient with a BRCA alteration. These challenging issues led the Italian Society for Uro-Oncology (SIUrO) to organise a Consensus Conference aimed to develop suggestions capable of supporting clinicians managing prostate cancer patients. The present paper described the development of the statements discussed during the consensus, which involved all of the most important Italian scientific societies engaged in the multi-disciplinary and multi-professional management of the disease.
Critical reviews in oncology/hematology. 2023 Mar 13 [Epub ahead of print]
Alberto Lapini, Orazio Caffo, Giario Natale Conti, Giovanni Pappagallo, Marzia Del Re, Rolando Maria D'Angelillo, Ettore Domenico Capoluongo, Francesca Castiglione, Matteo Brunelli, Roberto Iacovelli, Ugo De Giorgi, Sergio Bracarda
Department of Urology, University of Florence, University Hospital of Florence, Largo Brambilla, 3 - 50134 - Florence (Italy). Electronic address: ., Department of Medical Oncology, Santa Chiara Hospital, Largo Medaglie d'Oro - 38122 - Trento (Italy). Electronic address: ., Italian Society for Uro-Oncology (SIURO), Via Dante 17 - 40125 - Bologna (Italy). Electronic address: ., IRCCS "Sacro Cuore - Don Calabria", Viale Luigi Rizzardi, 4, 37024 Negrar di Valpolicella Negrar di Valpolicella (Italy). Electronic address: ., Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67 - 56126 - Pisa (Italy). Electronic address: ., Radiation Oncology, Department of Biomedicine and Prevention University of Rome "Tor Vergata", Viale Oxford 81 - 00133 - Rome (Italy). Electronic address: ., Department of Molecular Medicine and Medical Biotechnologies, University Federico II, Via Pansini 5 - 80131 - Naples (Italy); Department of Clinical Pathology and Genomics, Azienda Ospedaliera per L'Emergenza Cannizzaro, Via Messina 829 - 95126 - Catania (Italy). Electronic address: ., Department of Pathology, University of Florence, Largo Brambilla, 3 - 50134 - Florence (Italy). Electronic address: ., Unit of Pathology, Department of Diagnostics and Public Health, University of Verona, P.le L.A. Scuro 10 - 37134 -Verona (Italy). Electronic address: ., Medical Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8 - 00168 - Rome (Italy). Electronic address: ., Unit of Medical Oncology, IRCCS-Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Via Maroncelli 40 - 47014 - Meldola (Italy). Electronic address: ., Medical and Translational Oncology, Department of Oncology, Azienda Ospedaliera Santa Maria, Viale Tristano di Joannuccio - 05100 - Terni (Italy). Electronic address: .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/36921782